A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse

Joseph Moore*, Karen Seiter, Jonathan Kolitz, Wendy Stock, Francis Giles, Matt Kalaycio, David Zenk, Guido Marcucci

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse'. Together they form a unique fingerprint.

Medicine & Life Sciences